Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency
Conditions
Interventions
Placebo
AG-348
Locations
46
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Emory University
Atlanta, Georgia, United States
Indiana Hemophilia and Thrombosis Center
Indianapolis, Indiana, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
The Children's Hospital Corporation d/b/a Boston's Children Hospital
Boston, Massachusetts, United States
Wayne State University School of Medicine, Children's Hospital of Michigan
Detroit, Michigan, United States
Start Date
August 9, 2018
Primary Completion Date
October 9, 2020
Completion Date
October 9, 2020
Last Updated
May 24, 2022
NCT04170348
NCT06422351
NCT04964323
NCT03559699
NCT00749112
Lead Sponsor
Agios Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions